Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% year-over-year [6][12] - For the full year 2025, total sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates, which is at the upper end of the guidance [14][15] - Business EPS growth was strong at 26.7%, indicating effective operational leverage [12] - Business gross margin expanded by 1.8 percentage points to 77.5%, driven by a favorable product mix and operational efficiencies [14] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines generated EUR 5.7 billion in sales, with a growth of 34% in 2025 [4][6] - Dupixent sales reached EUR 4.2 billion in Q4 and EUR 15.7 billion for the full year, with over 30% increase in patient numbers [7][8] - Beyfortus sales grew by 9.5% to EUR 1.8 billion, driven by geographic expansion [8][9] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full-year sales of EUR 7.9 billion [8] - The U.S. market share for influenza vaccines increased, particularly with Fluzone High-Dose and Flublok [8] - Beyfortus has protected over 11 million babies in more than 45 countries, preventing an estimated 200,000 hospitalizations [9] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma entity, focusing on business development and M&A opportunities [4] - Strategic acquisitions, including Vicebio and Dynavax Technologies, are aimed at enhancing the vaccine portfolio and expanding into older adult markets [9][10][17] - The company plans to continue investing in manufacturing capacity to meet growing patient demand [14] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver high single-digit growth in sales and business EPS to grow slightly faster than sales [18] - The company anticipates a decline in vaccine sales in 2026 but expects gross margin expansion to continue [18] - Management highlighted the importance of maintaining a strong capital structure and financial flexibility for future growth opportunities [16] Other Important Information - The company completed a EUR 5 billion share buyback program and proposed a 5% increase in dividends for the 31st consecutive year [17] - The company aims for a free cash flow of at least 20% of net sales in the medium term, with a strong cash flow generation of EUR 8.1 billion in 2025 [15] Q&A Session Summary Question: Can you elaborate on the Dupixent rollout and its competition? - Management reported strong performance with 25% growth year-over-year for Dupixent, driven by new indications like CSU and COPD [30][31] - The penetration rates for Dupixent in AD and CSU are still low, indicating room for market growth [32] Question: What is the outlook for Beyfortus in 2026? - Beyfortus had a 9% increase in 2025, with expectations for continued geographic expansion [34][35] Question: What are the prospects for Amlitelimab? - Management remains confident in Amlitelimab's potential, emphasizing its novel mechanism and the importance of data-driven decisions [39][41] Question: Can you provide details on the Kaposi sarcoma case related to Amlitelimab? - Management clarified that Kaposi sarcoma is associated with herpes virus and is not considered a significant concern for Amlitelimab [46][49] Question: What is the capital allocation strategy moving forward? - The company plans to dynamically allocate resources based on value, with an increase in business development activity expected [60][75]

Core Viewpoint - The company, Nocera Biopharma, announced that it expects to achieve profitability for the first time in 2025, with a projected net profit of approximately 633 million yuan, an increase of about 1.074 billion yuan compared to the same period last year [1] Financial Performance - The company anticipates total operating revenue of approximately 2.365 billion yuan in 2025, representing a growth of around 134% compared to the previous year [1]

（文章来源：证券日报） 证券日报网讯 1月29日，康泰生物发布公告称，公司预计2025年归属于上市公司股东的净利润为4900万 元至7300万元，同比下降75.70%至63.80%。 ...

Group 1 - The core viewpoint of the article highlights Shenzhen Kangtai Biological Products Co., Ltd.'s transformation into a global innovative biopharmaceutical company, with significant growth in R&D investment and overseas business revenue [1][2] - In 2025, the company expects a net profit attributable to shareholders of between 49 million to 73 million yuan, with overseas business revenue reaching approximately 98.84 million yuan, reflecting a year-on-year growth of 859.40% [1] - R&D investment is projected to be around 633 million yuan, marking an 11.25% increase compared to the previous year [1] Group 2 - The company has made key progress in expanding its overseas market, with multiple core vaccine products obtaining overseas GMP certification or registration, covering over 20 countries [2] - Kangtai Biological is leveraging AI technology to enhance vaccine innovation, participating in industry exchanges and establishing a key laboratory in collaboration with the Chinese Academy of Sciences [2] - The company aims to accelerate its transformation by focusing on R&D-driven strategies, deepening international layouts, and embracing AI to enhance the entire vaccine development and production process [3]

证券日报网讯 1月29日，诺诚健华在互动平台回答投资者提问时表示，公司上市以来管线推进迅速，营 业收入实现加速增长，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业 总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿 元左右。 （编辑 姚尧） ...

（编辑 姚尧） 证券日报网讯 1月29日，诺诚健华在互动平台回答投资者提问时表示，公司与Zenas交易不仅为公司带 来了实质性的即期财务收益，进一步增强了公司的现金储备与资产结构，里程碑付款可以为公司带来可 持续的现金流与长期收益，此次合作也将有助于最大化奥布替尼在全球范围内的临床与商业价值，使产 品能够更快惠及全球患者，也充分体现了公司创新资产的国际竞争力与长期商业潜力。公司未来也会持 续推进全球化战略，以"自主创新+合作共赢"的模式加速创新成果在全球范围的临床开发与商业转化。 ...

Core Viewpoint - ST Unimed (002581.SZ) forecasts a significant loss for the fiscal year 2025, with projected revenue between 355 million to 398 million yuan and a net loss attributable to shareholders ranging from 55 million to 90 million yuan, compared to a loss of 137 million yuan in the same period last year [1] Financial Performance - The company expects to report a revenue of 355 million to 398 million yuan for the fiscal year 2025 [1] - The net loss attributable to shareholders is projected to be between 55 million to 90 million yuan, an improvement from the previous year's loss of 137 million yuan [1] - The net profit after deducting non-recurring gains and losses is anticipated to be a loss of 70 million to 105 million yuan, compared to a loss of 111 million yuan in the previous year [1] Operational Challenges - The primary reason for the company's losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has adversely affected related business revenue [1] - The company is actively working on rectification to promote the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]

Group 1 - The company, I-Woo Bio (300357), stated that it will fulfill its information disclosure obligations according to the relevant requirements of the "Performance Forecast and Performance Express" section of the Shenzhen Stock Exchange's Growth Enterprise Market listing rules [1]

Core Viewpoint - The company Yifang Biotech (688382.SH) has announced an expected net loss of 292 million yuan for the fiscal year 2025, primarily due to high R&D investment and revenue composition changes [1]. Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1]. - The financial performance is significantly influenced by the intensity of R&D investments and the structure of revenue [1]. Group 2: R&D Progress - The company is advancing multiple core clinical projects, with several entering critical stages and showing positive progress [1]. - The oral selective estrogen receptor degrader (SERD) D0502 is undergoing a Phase III clinical trial for second-line treatment in China [1]. - The TYK2 inhibitor D-2570 has initiated clinical explorations in various autoimmune diseases, including a Phase II trial for ulcerative colitis and a Phase III trial for psoriasis in China, as well as a Phase I trial in the United States [1]. - The URAT1 inhibitor D-0120 has completed follow-up in a Phase II clinical trial in the U.S. and is expected to finish all research work by the first quarter of 2026 [1]. Group 3: Preclinical Pipeline - The company has made significant progress in its preclinical pipeline, with two innovative candidates, WRN inhibitor YF087 and KIF18A inhibitor YF550, demonstrating strong anti-tumor potential in various preclinical studies [2]. - Ongoing IND supportive research is being conducted to prepare these candidates for clinical stages [2]. - The company continues to invest in early-stage R&D, including the development of other candidate drugs, innovative technology platform construction, and early drug discovery to build momentum for long-term growth [2].

Core Viewpoint - ST Unimed (002581.SZ) forecasts a significant loss for the fiscal year 2025, with expected revenue between 355 million to 398 million yuan and a net loss attributable to shareholders ranging from 55 million to 90 million yuan, compared to a loss of 137 million yuan in the same period last year [1] Financial Performance - The company anticipates a revenue of 355 million to 398 million yuan for the reporting period [1] - The net loss attributable to shareholders is projected to be between 55 million to 90 million yuan, an improvement from the previous year's loss of 137 million yuan [1] - The net profit after excluding non-recurring gains and losses is expected to be a loss of 70 million to 105 million yuan, compared to a loss of 111 million yuan in the same period last year [1] Operational Challenges - The primary reason for the company's losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has adversely affected related business revenue [1] - The company is actively working on rectification to expedite the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]